(acquired by IBM)
|$2.18 to $73.20||3487%|
|$2.35 to $24.08||925%|
|Cellstar||$1.44 to $13.50||837%|
|Iomega||$3.25 to $13.90||328%|
|Nanophase||$3.75 to $16.75||347%|
|Immunomedics||$1.44 to $29.12||1922%|
|Total Renal Care||$3.12 to $26.95||741%|
|Voxware||$ .90 to $10.31||1046%|
|Corvas||$3.00 to $23.25||675%|
|Cytogen||$2.12 to $17.50||725%|
|Verilink||$3.00 to $14.62||387%|
|GeneLabs||$2.31 to $10.72||364%|
THE LATE MAY NEWSLETTER IS NOW POSTED!!!!
Both of our picks are biotechs that are STRONG BUYS/BUYS of three or more analysts.
One is a Channeled stock trading at around $1.70 that recently received orphan designation from the FDA for 3D bioprinting.
The other pick is around $2.90 and develops therapeutics to combat cancer. This company has strategic alliances with Celgene and Bayer Pharma. To date, it has advanced 14 INDs and initiated 27 clinical studies that have enrolled more than 1300 subjects.
"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"
— B.K. (Contractor in Saudi Arabia)